These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


457 related items for PubMed ID: 26241002

  • 21. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.
    Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, Wang C, Vasudevan SG, Jans DA.
    Antiviral Res; 2013 Sep; 99(3):301-6. PubMed ID: 23769930
    [Abstract] [Full Text] [Related]

  • 22. Dengue Virus Evolution under a Host-Targeted Antiviral.
    Plummer E, Buck MD, Sanchez M, Greenbaum JA, Turner J, Grewal R, Klose B, Sampath A, Warfield KL, Peters B, Ramstedt U, Shresta S.
    J Virol; 2015 May; 89(10):5592-601. PubMed ID: 25762732
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus.
    Franco EJ, Pires de Mello CP, Brown AN.
    Viruses; 2021 Apr 27; 13(5):. PubMed ID: 33925551
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of dengue antiviral candidates in vivo in mouse model.
    Watanabe S, Vasudevan SG.
    Methods Mol Biol; 2014 Apr 27; 1138():391-400. PubMed ID: 24696350
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Sophoraflavenone G Restricts Dengue and Zika Virus Infection via RNA Polymerase Interference.
    Sze A, Olagnier D, Hadj SB, Han X, Tian XH, Xu HT, Yang L, Shi Q, Wang P, Wainberg MA, Wu JH, Lin R.
    Viruses; 2017 Oct 03; 9(10):. PubMed ID: 28972551
    [Abstract] [Full Text] [Related]

  • 28. An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target.
    Howe MK, Speer BL, Hughes PF, Loiselle DR, Vasudevan S, Haystead TA.
    Antiviral Res; 2016 Jun 03; 130():81-92. PubMed ID: 27058774
    [Abstract] [Full Text] [Related]

  • 29. Sofosbuvir as treatment against dengue?
    Gan CS, Lim SK, Chee CF, Yusof R, Heh CH.
    Chem Biol Drug Des; 2018 Feb 03; 91(2):448-455. PubMed ID: 28834304
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Strategies for development of Dengue virus inhibitors.
    Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY.
    Antiviral Res; 2010 Mar 03; 85(3):450-62. PubMed ID: 20060421
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Repurposing of prochlorperazine for use against dengue virus infection.
    Simanjuntak Y, Liang JJ, Lee YL, Lin YL.
    J Infect Dis; 2015 Feb 01; 211(3):394-404. PubMed ID: 25028694
    [Abstract] [Full Text] [Related]

  • 36. Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors.
    Bardiot D, Koukni M, Smets W, Carlens G, McNaughton M, Kaptein S, Dallmeier K, Chaltin P, Neyts J, Marchand A.
    J Med Chem; 2018 Sep 27; 61(18):8390-8401. PubMed ID: 30149709
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.
    Ayala-Nuñez NV, Jarupathirun P, Kaptein SJ, Neyts J, Smit JM.
    Antiviral Res; 2013 Oct 27; 100(1):238-45. PubMed ID: 23994499
    [Abstract] [Full Text] [Related]

  • 39. Antiviral activity of ST081006 against the dengue virus.
    Lee JK, Chui JLM, Lee RCH, Kong HY, Chin WX, Chu JJH.
    Antiviral Res; 2019 Nov 27; 171():104589. PubMed ID: 31421165
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 23.